apixaban: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
apixaban: clinical details
Prescribing considerations
- Confirm the licensed indication and that the formulation suits the patient's age and swallowing or enteral-access needs.
- Assess bleeding and thrombosis risks, renal and hepatic function, body weight, comorbidity and interacting medicines.
- Coordinate peri-procedural interruption and restart according to bleeding risk and haemostasis.
- Use caution with older age, frailty, low body weight, renal impairment, active cancer or other increased bleeding risks.
- Apixaban is not recommended for prosthetic heart valves, triple-positive antiphospholipid syndrome or haemodynamically unstable pulmonary embolism requiring thrombolysis or embolectomy.
Contraindications and cautions
- Hypersensitivity to apixaban or a formulation excipient
- Active clinically significant bleeding
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
- A lesion or condition carrying a significant risk of major bleeding
- Concurrent anticoagulation except in circumstances permitted by the product information
Monitoring
- Before treatment, assess full blood count, liver function, urea and electrolytes, body weight and renal function using creatinine clearance rather than eGFR alone.
- Review adherence, bleeding, anaemia, thromboembolic symptoms, interactions and continuing indication.
- Repeat full blood count, liver and renal tests periodically, with closer review in frailty, older age, renal impairment, intercurrent illness or changing hepatic function.
- Routine INR or exposure monitoring is not required. A calibrated apixaban anti-factor Xa assay may assist in selected emergencies such as overdose or urgent surgery.
Clinical pharmacology
Apixaban is a direct, selective and reversible factor Xa inhibitor. Oral bioavailability is approximately half, protein binding is high, and elimination uses renal and non-renal pathways. CYP3A4/5 and P-glycoprotein contribute to important interactions.
Formulation and product differences
- Selected products include film-coated tablets and ready-made oral suspensions.
- Tablets may be crushed for prompt oral administration and, where product instructions permit, delivery through a nasogastric tube.
- Oral suspensions must be shaken before measurement and given with the supplied oral syringe and bottle adaptor.
- Suspension excipients differ between manufacturers and may include sodium benzoate, propylene glycol or sorbitol; check the exact product information when sensitivity or intolerance matters.
apixaban preparations and strengths
Oral suspension
Route: Oral
Strengths: 1 mg/1 mL, 1 mg/mL
Tablet
Route: Oral
Strengths: 2.5 mg, 5 mg
apixaban interactions
Interactions can increase bleeding or make apixaban less effective. Check prescribed, over-the-counter and herbal products before use.
Other anticoagulants
Usually avoid concurrent treatment because bleeding risk rises, except during carefully managed switching or specific specialist situations.
Antiplatelets such as aspirin, clopidogrel or ticagrelor
Can increase bleeding risk and should only be combined when clinically justified and reviewed.
NSAIDs such as ibuprofen or naproxen
May increase bleeding; check with a pharmacist or prescriber before use.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.